RNF213 Mutation Associated with the Progression from Middle Cerebral Artery Steno-Occlusive Disease to Moyamoya Disease
Translational Stroke Research · 2025
DOI: 10.1007/s12975-024-01293-2 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Translational Stroke Research, 2025. Verfasst von Tomoki Sasagasako und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Adenosine Triphosphatases, Infarction, Middle Cerebral Artery, Moyamoya Disease, Mutation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology of Japan, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Middle cerebral artery steno-occlusive disease (MCAD) has been recognized as a different clinical entity from moyamoya disease (MMD). Although MCAD can progress to MMD, the extent to which patients actually progress and the risk factors for this progression have not been fully elucidated. We retrospectively reviewed patients with MCAD who underwent RNF213 genotyping. Demographic features, RNF213 p.R4810K mutation, medical history, and longitudinal changes in angiography were analyzed. Sixty patients with 81 affected hemispheres were enrolled. During the follow-up period, 17 patients developed MMD, and the RNF213 p.R4810K mutation was the only factor significantly associated with progression to MMD (odds ratio, 16.1; 95% CI, 2.13–731; P = 0.001). The log-rank test demonstrated that patients with the mutation had a higher risk of progression to MMD ( P = 0.007), stenosis progression ( P = 0.010), and symptomatic cerebral infarction or hemorrhage ( P = 0.026). In Cox regression analysis the p.R4810K mutation remained a significant factor after adjusting for age group (childhood or adult onset) at diagnosis (hazard ratio, 8.42; 95% CI, 1.10–64.4). Hemisphere-based analysis also showed that the mutation was associated with a higher risk of progression to the MMD hemisphere ( P = 0.002), stenosis progression ( P = 0.005), and cerebral infarction or hemorrhage ( P = 0.012). The RNF213 p.R4810K mutation was identified as a risk factor for progression from MCAD to MMD. Genotyping for this mutation may contribute to risk stratification in MCAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Neurosurgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. mineharu@kuhp.kyoto-u.ac.jp.
- Department of Neurosurgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. tfunaki@kuhp.kyoto-u.ac.jp.
- Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Förderung
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- Japan Agency for Medical Research and Development
Zitieren
APA
Sasagasako, T., Mineharu, Y., Funaki, T., Fushimi, Y., Chihara, H., Park, S., Nakajima, K., Matsui, Y., Okawa, M., Kikuchi, T., & Arakawa, Y. (2025). RNF213 Mutation Associated with the Progression from Middle Cerebral Artery Steno-Occlusive Disease to Moyamoya Disease. Translational Stroke Research. https://doi.org/10.1007/s12975-024-01293-2
Vancouver
Sasagasako T, Mineharu Y, Funaki T, Fushimi Y, Chihara H, Park S, et al. RNF213 Mutation Associated with the Progression from Middle Cerebral Artery Steno-Occlusive Disease to Moyamoya Disease. Translational Stroke Research. 2025. doi:10.1007/s12975-024-01293-2
BibTeX
@article{Sasagasako2025,
author = {Sasagasako, Tomoki and Mineharu, Yohei and Funaki, Takeshi and Fushimi, Yasutaka and Chihara, Hideo and Park, Silsu and Nakajima, Kota and Matsui, Yasuzumi and Okawa, Masakazu and Kikuchi, Takayuki and Arakawa, Yoshiki},
title = {RNF213 Mutation Associated with the Progression from Middle Cerebral Artery Steno-Occlusive Disease to Moyamoya Disease},
journal = {Translational Stroke Research},
year = {2025},
doi = {10.1007/s12975-024-01293-2}
}
EUVIMED